Assembly Biosciences’ (ASMB) Neutral Rating Reiterated at Chardan Capital

Chardan Capital reissued their neutral rating on shares of Assembly Biosciences (NASDAQ:ASMB) in a report published on Sunday.

ASMB has been the subject of a number of other reports. ValuEngine lowered shares of Assembly Biosciences from a buy rating to a hold rating in a research note on Wednesday, October 3rd. B. Riley raised shares of Assembly Biosciences from a neutral rating to a buy rating and set a $42.00 price objective for the company in a research note on Monday, October 8th. Zacks Investment Research lowered shares of Assembly Biosciences from a hold rating to a sell rating in a research note on Monday, August 13th. Robert W. Baird started coverage on shares of Assembly Biosciences in a research note on Wednesday, August 8th. They set an outperform rating and a $74.00 price objective for the company. Finally, BidaskClub lowered shares of Assembly Biosciences from a sell rating to a strong sell rating in a research note on Friday, July 13th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of Hold and an average price target of $62.60.

NASDAQ ASMB traded up $0.41 on Friday, reaching $23.29. The company’s stock had a trading volume of 48,313 shares, compared to its average volume of 238,963. Assembly Biosciences has a twelve month low of $20.61 and a twelve month high of $67.36. The company has a market capitalization of $566.44 million, a price-to-earnings ratio of -9.66 and a beta of 0.79.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($1.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.42). Assembly Biosciences had a negative net margin of 457.20% and a negative return on equity of 66.34%. The firm had revenue of $3.22 million for the quarter, compared to analysts’ expectations of $3.30 million. On average, sell-side analysts anticipate that Assembly Biosciences will post -4.02 EPS for the current year.

In other Assembly Biosciences news, insider Uri A. Lopatin sold 15,540 shares of the company’s stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $40.09, for a total transaction of $622,998.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 18.20% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the business. Prosight Management LP purchased a new stake in Assembly Biosciences during the second quarter valued at about $2,560,000. MetLife Investment Advisors LLC purchased a new stake in shares of Assembly Biosciences in the second quarter worth approximately $282,000. Jane Street Group LLC purchased a new stake in shares of Assembly Biosciences in the first quarter worth approximately $204,000. Quantitative Systematic Strategies LLC purchased a new stake in shares of Assembly Biosciences in the second quarter worth approximately $348,000. Finally, Fred Alger Management Inc. lifted its position in shares of Assembly Biosciences by 42.9% in the second quarter. Fred Alger Management Inc. now owns 10,000 shares of the biopharmaceutical company’s stock worth $392,000 after purchasing an additional 3,000 shares in the last quarter. 65.28% of the stock is owned by institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

Further Reading: Insider Trading

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply